Halliburton enters the first week of June with an awkward split: the Street is becoming more constructive, yet short sellers have spent the past month quietly rebuilding their positions against the stock.
The analyst shift is the clearest new signal this week. Citigroup's Scott Gruber lifted his target from $47 to $52 this morning — the second time he has raised it since late April — while reiterating Buy. That follows Barclays upgrading HAL to Overweight in early May, moving its target from $37 to $55. Virtually every major house that published after Halliburton's Q1 print on April 23 moved targets higher: JPMorgan, Morgan Stanley, RBC, and Stifel all revised upward. The consensus mean price target now sits at $43.88 against a close of $40.13, implying a gap of nearly 9%. The analyst recommendation divergence factor ranks in the 90th percentile of the ORTEX universe — a notably wide gap between where the stock trades and where the Street thinks it belongs.
Short interest, however, is telling a different story. Bearish positioning has climbed roughly 14% over the past month, with the estimated short position reaching 3.9% of free float as of June 2. The week-on-week increase was close to 9% — the sharpest weekly build in at least six weeks. That pace of rebuilding is worth noting even if the absolute level is not extreme. Cost to borrow remains loose at 0.48% — well inside what any squeeze pressure would require — and borrow availability is effectively unconstrained at nearly 9,900% of current short interest, meaning there are roughly 100 shares available to lend for every one currently borrowed. The ORTEX short score has drifted modestly higher over the past two weeks, from 33.2 to 34.5, but remains in mid-range territory with no sign of urgency on either side.
Options positioning has eased away from caution. The put/call ratio has slipped to 0.796, below its 20-day average of 0.830, placing it about 1.4 standard deviations on the bullish side. That is the least defensive options setup for HAL in several weeks. Combined with abundant borrow availability and a moderate short score, the lending market offers no sign of meaningful squeeze dynamics — this looks more like tactical repositioning than a coordinated bear thesis.
The bull case rests on Halliburton's dominant completions and hydraulic fracturing franchise and a balance sheet that carries a debt-to-equity ratio around 0.48. The bear case centres on declining U.S. activity levels and Middle East exposure that could compress margins through the back half of the year. The valuation picture sits in the middle: trailing PE is around 15.5x — down more than one turn over the past month — while EV/EBITDA is approximately 9.2x. The EPS surprise score ranks in the 67th percentile, suggesting Halliburton has been a moderate but consistent outperformer versus estimates. Peers are not immune to the same forces; SLB fell 2.4% on the week and BKR dropped 3.3%, confirming this is a sector-wide drift rather than Halliburton-specific pressure.
Insider activity has leaned toward selling in recent months. The Chief Legal Officer sold roughly $8.2 million worth of stock in mid-May at $41.29, the largest disclosed transaction in the 90-day window. The CEO sold $6.3 million in late March. Net insider selling across 90 days totals approximately $28.8 million across the cohort. None of these trades carry a high significance score individually, and sales by legal officers and treasurers often reflect pre-planned programmes rather than views on the stock — but the one-way direction is worth registering.
Q1 results on April 23 produced a 3.2% single-day gain and an 8.2% five-day move, affirming the stock has rewarded holders through recent prints. The next event is pencilled in for July 20. Between now and then, the question is whether the short rebuild has momentum behind it — or whether the growing gap between the consensus target and the current price eventually closes the other way.
See the live data behind this article on ORTEX.
Open HAL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
